Resources

12 Resources for

healthcare and neil carvin

Subscribe to this listing via:
RSS
Email

BNET Resources

Parsing King Pharma's Q1: Neil Carvin submits: King Pharmaceuticals KG lost $0.04 per share in the three months that ended on 31 March 2009, compared to earnings of $0.35 per share in the year-earlier quarter. The results were announced in this press release and, soon after, in a formal 10-Q report. ...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-05-13
King Pharma's June Results: A Look Ahead: Neil Carvin submits: The GCFR Overall Gauge of King Pharmaceuticals (NYSE: KG) edged up from 23 to 26 of the 100 possible points in the first quarter of 2009, which ended on 31 March. Our analysis report explained this result in some detail. The March quarter...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-06-29
Watson Pharma Income Statement Analysis for June 2009 Quarter: Neil Carvin submits: Watson Pharmaceuticals, Inc. (NYSE: WPI) earned $0.46 per share during the three months that ended on 30 June 2009, down from $0.51 in last year's second quarter. This post examines the Income Statement for the quarter and compares it to our "look-ahead" estimates....; Tags: Healthcare, Neil Carvin, Watson Pharmaceuticals Inc.; External links 2009-07-30
Watson Pharma Financial Gauge Analysis for June 2009 Quarter: Neil Carvin submits: In an earlier post, we examined Watson Pharmaceuticals' (NYSE: WPI) Income Statement for the June quarter and compared the figures to our "look-ahead" estimates. Second-quarter earnings fell from $0.51 to $0.46 per share, primarily because of the costs to launch the RAPAFLO and Gelnique...; Tags: Healthcare, Neil Carvin, Watson Pharmaceuticals Inc.; External links 2009-08-04
King Pharma: Income Statement Analysis for the June 2009 Quarter: Neil Carvin submits: King Pharmaceuticals, Inc. (NYSE: KG) earned $0.15 per share in the three months that ended on 30 June 2009, down from $0.17 per share in the second quarter of last year. On a non-GAAP ("pro forma" or "ex-items") basis, King's earnings slipped from...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-08-07

King Pharma Financial Gauge Analysis for June 2009 Quarter: Neil Carvin submits: In an earlier post, we examined King Pharmaceuticals' (NYSE: KG) Income Statement for the three months that ended 30 June 2009. Second-quarter earnings fell from $0.17 last year to $0.15 per share. Non-GAAP earnings per share slipped from $0.35 to $0.32. by...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-08-18
Watson Pharma Look-Ahead to September 2009 Quarterly Results: Neil Carvin submits: The GCFR Overall Gauge of Watson Pharmaceuticals, Inc. (NYSE: WPI) slipped from 43 to 39 of the 100 possible points in the second quarter of 2009. Our income statement and financial gauge analyses explained in some detail how the score was attained....; Tags: Healthcare, Neil Carvin, Watson Pharmaceuticals Inc.; External links 2009-09-23
King Pharma Look-Ahead to September 2009 Quarterly Results: Neil Carvin submits: The GCFR Overall Gauge of King Pharmaceuticals (NYSE: KG) dropped from 28 to 18 of the 100 possible points in the second quarter of 2009. Our income statement and financial gauge analysis reports explained this result in some detail. by Neil Carvin; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-09-25
Watson Pharmaceuticals: Income Statement Analysis for the September 2009 Quarter: Neil Carvin submits: Watson Pharmaceuticals, Inc. WPI earned $0.54 per share in the third quarter of 2009, down from $0.60 in the same quarter of last year. [Note: our per-share numbers are slightly different than the official results because we don't adjust for interest expenses on convertible contingent...; Tags: Healthcare, Neil Carvin, Watson Pharmaceuticals Inc.; External links 2009-11-08
King Pharma Income Statement Analysis for September 2009 Quarter: Neil Carvin submits: King Pharmaceuticals, Inc. (NYSE: KG) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non-GAAP ("pro forma" or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-11-09
Watson Pharmaceutical Financial Gauge Analysis for the September 2009 Quarter: Neil Carvin submits: In a previous article, we examined Watson Pharmaceuticals' WPI Income Statement for the third quarter of 2009 and compared the entries on each line to our "look-ahead" estimates. Earnings in this period, which ended 30 September 2009, fell from $0.60 to $0.54 per share. ...; Tags: Healthcare, Neil Carvin, Watson Pharmaceuticals Inc.; External links 2009-11-25
King Pharmaceuticals Financial Gauge Analysis for September 2009 Quarter: Neil Carvin submits: In a previous article, we examined King Pharmaceuticals' (NYSE: KG) Income Statement for the third quarter of 2009 and compared the entries on each line to our "look-ahead" estimates. Earnings in this period, which ended 30 September 2009, fell from $0.34...; Tags: Healthcare, Neil Carvin, King Pharmaceuticals Inc.; External links 2009-11-30